Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $0.74, in-line with the analyst estimate of $0.74. Revenue for the quarter came in at $5.14 billion versus the consensus estimate of $5.09 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2017 EPS of $2.90-$3.00, versus the consensus of $2.95.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.